14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MPTI vs VREX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Varex Imaging Corporation (VREX) captures the overall head-to-head institutional edge over M-tron Industries, Inc. (MPTI) on higher Unified Composite conviction (54.8/100 HOLD vs. 37.1/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Growth & Scale), while MPTI wins 3–2 across the 6-pillar growth and valuation breakdown. MPTI trades at $63.24 (19.8x Forward P/E, 17.8% operating margin) versus VREX at $18.10 (16.9x Forward P/E, 8.3% operating margin).
Growth vs. Quality Trade-Off: VREX earns the overall head-to-head edge with a stronger Unified Composite Score (54.8/100 HOLD vs. MPTI 37.1/100 SELL) and 0.65β · 5% Vol risk profile, whereas MPTI leads top-line expansion (+11.1% YoY revenue growth, 1.05x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: MPTI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.0); meanwhile VREX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 28.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MPTI vs VREX. Trailing 12-month operating profitability (MPTI 17.8% vs VREX 8.3%) and valuation multiples (MPTI 19.8x vs VREX 16.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $770.3M market capitalization and 8.3% operating margin.
OpEx & R&D Reinvestment26.0% of Rev ($225M)
90D Engineering Disclosures0 Published
Investor FAQ MPTI vs VREX Key Questions & Quantitative Answers
As of Nov 20, 2026, Varex Imaging Corporation (VREX) captures the overall head-to-head institutional edge over M-tron Industries, Inc. (MPTI) on higher Unified Composite conviction (54.8/100 HOLD vs. 37.1/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Growth & Scale), while MPTI wins 3–2 across the 6-pillar growth and valuation breakdown. MPTI trades at $63.24 (19.8x Forward P/E, 17.8% operating margin) versus VREX at $18.10 (16.9x Forward P/E, 8.3% operating margin). Growth vs. Quality Trade-Off: VREX earns the overall head-to-head edge with a stronger Unified Composite Score (54.8/100 HOLD vs. MPTI 37.1/100 SELL) and 0.65β · 5% Vol risk profile, whereas MPTI leads top-line expansion (+11.1% YoY revenue growth, 1.05x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MPTI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.0); meanwhile VREX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 28.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VREX leads the Growth & Scale pillar: MPTI posts +11.1% YoY revenue growth and +16.7% YoY earnings growth on $60M TTM revenue (44.3% gross margin, 17.8% operating margin), compared with VREX at +3.7% YoY revenue growth and +453.4% YoY earnings growth on $865M TTM revenue (34.3% gross margin, 8.3% operating margin). On trailing 12-month operating scale, MPTI generates $60M in USD-normalized revenue versus $865M for VREX. In operating R&D and SG&A reinvestment, MPTI deploys 26.5% of Rev ($16M) (0 90-day corporate R&D disclosures) versus 26.0% of Rev ($225M) (0 disclosures) for VREX.
VREX screens cheaper on headline valuation multiples. MPTI trades at 19.8x Forward P/E, 24.8x Trailing P/E, 1.05x PEG, and 3.9x EV/Revenue (14.6% FCF margin), whereas VREX trades at 16.9x Forward P/E, 34.2x Trailing P/E, 6.30x PEG, and 0.9x EV/Revenue (11.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MPTI (13.5% ROE) versus VREX (4.6% ROE) capital efficiency.
In options market volatility and institutional positioning, MPTI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.67β · 64% Vol realized risk). By comparison, VREX carries 112.0% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 5% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.